The 36-month beta value for IFRX is also noteworthy at 1.58. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for IFRX is 48.83M, and at present, short sellers hold a 0.54% of that float. The average trading volume of IFRX on October 25, 2024 was 70.92K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
IFRX) stock’s latest price update
InflaRx N.V. (NASDAQ: IFRX)’s stock price has soared by 7.38 in relation to previous closing price of 1.49. Nevertheless, the company has seen a gain of 3.23% in its stock price over the last five trading days. globenewswire.com reported 2024-09-25 that JENA, Germany, Sept. 25, 2024 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced the e-poster presentation of a post hoc analysis of the SHINE Phase 2b study of its first-in-class anti-C5a antibody, vilobelimab, in hidradenitis suppurativa (HS) at the 2024 European Academy of Dermatology and Venereology (EADV) Congress being held in Amsterdam, September 25 – 28, 2024.
IFRX’s Market Performance
IFRX’s stock has risen by 3.23% in the past week, with a monthly rise of 5.26% and a quarterly rise of 4.58%. The volatility ratio for the week is 6.45% while the volatility levels for the last 30 days are 5.24% for InflaRx N.V. The simple moving average for the past 20 days is 4.81% for IFRX’s stock, with a 4.51% simple moving average for the past 200 days.
Analysts’ Opinion of IFRX
Many brokerage firms have already submitted their reports for IFRX stocks, with Guggenheim repeating the rating for IFRX by listing it as a “Buy.” The predicted price for IFRX in the upcoming period, according to Guggenheim is $8 based on the research report published on April 05, 2023 of the previous year 2023.
Raymond James gave a rating of “Strong Buy” to IFRX, setting the target price at $14 in the report published on October 28th of the previous year.
IFRX Trading at 5.58% from the 50-Day Moving Average
After a stumble in the market that brought IFRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -23.81% of loss for the given period.
Volatility was left at 5.24%, however, over the last 30 days, the volatility rate increased by 6.45%, as shares surge +3.90% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +18.52% upper at present.
During the last 5 trading sessions, IFRX rose by +3.23%, which changed the moving average for the period of 200-days by -21.18% in comparison to the 20-day moving average, which settled at $1.5265. In addition, InflaRx N.V. saw -1.84% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for IFRX
Current profitability levels for the company are sitting at:
- -492.02 for the present operating margin
- -10.01 for the gross margin
The net margin for InflaRx N.V. stands at -441.03. The total capital return value is set at -0.63. Equity return is now at value -45.19, with -41.36 for asset returns.
Based on InflaRx N.V. (IFRX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -42.62. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -1353.49.
Currently, EBITDA for the company is -56.38 million with net debt to EBITDA at 0.36. When we switch over and look at the enterprise to sales, we see a ratio of 651.86. The receivables turnover for the company is 0.06for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.91.
Conclusion
In summary, InflaRx N.V. (IFRX) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
